Tesaro files for IPO

Tesaro Inc. (Waltham, Mass.) proposed to raise up to $86.3 million in an IPO underwritten by Citi; Morgan Stanley; Leerink; BMO Capital Markets; and Baird. Tesaro's rolapitant is in Phase III testing to prevent chemotherapy-induced nausea and vomiting (CINV), with top-line data expected in 2H13. Tesaro has exclusive, worldwide rights to the neurokinin 1 (NK1) substance P receptor (TACR1) antagonist from Opko Health Inc. (NYSE:OPK). Tesaro was founded in 2010 by three former senior executives of MGI Pharma Inc. (see BioCentury, March 7, 2011). ...